Quest Diagnostics Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Quest Diagnostics (DGX) reported robust third-quarter 2026 financial results, characterized by a 10.0% increase in net revenues to $3.1 billion and a significant rise in adjusted diluted EPS to $3.00, up 15.4% year-over-year. Growth was primarily driven by a 14.5% surge in requisition volume, bolstered significantly by strategic partnerships with Corewell Health and Fresenius Medical Care. On the back of strong organic operating performance and margin expansion through its 'Invigorate' productivity program, the company raised its full-year 2026 revenue and adjusted EPS guidance. While management noted potential regulatory headwinds from PAMA rate-setting in 2027, current momentum remains high across physician, hospital, and consumer health channels.
Topics: EPS Increase Guidance Raise Operating Margin Partnerships Revenue Growth